Docoh
Loading...

PRPO Precipio

Filed: 3 Dec 03, 7:00pm
                                                                    Exhibit 99.1

            Transgenomic's WAVE(R) System Advances Study of Genetic
                        Variation Implicated In Leukemia

       Technology Offers Novel Approach to Analysis of Key Drug Targets

    LOS ANGELES, Dec. 4 /PRNewswire-FirstCall/ -- Transgenomic Inc.
(Nasdaq: TBIO) announced today that its WAVE System will be cited in several
presentations at the American Society of Hematology (ASH) annual meeting,
Dec. 6-8 in San Diego, Calif. Two of these presentations involve the analysis
of genes that have been implicated in the pathogenesis of leukemia and
identified as targets for therapeutic intervention.
    (Logo: http://www.newscom.com/cgi-bin/prnh/20000314/CGTU026 )
    A research team led by Giovanni Martinelli, M.D., has used Transgenomic's
WAVE System in two leukemia-related studies. The first describes detection of
mutations in the BCR-ABL gene that are potentially associated with resistance
to therapy with the novel tyrosine kinase inhibitor imatinib in chronic
myeloid leukemia patients. The other study involves detection of small
duplications and point mutations in the FLT3 gene, which has been implicated
in the pathogenesis of acute myeloid leukemia and is the target of several
investigational drugs.
    The group's work on the FLT3 gene has also resulted in two recent
publications in the October issues of Clinical Chemistry and The Lancet
Oncology. Dr. Martinelli commented on the significance of this body of work
and the role of the WAVE System. "Several FLT3 inhibitors are under
investigation for treatment of acute myelogenous leukemia. These drug
candidates have varying degrees of effectiveness against leukemic cells with
different FLT3 abnormalities, making thorough analysis of the FLT3 gene in
patient populations critical." Dr. Martinelli continued, "The traditional
approach of screening for FLT3 alterations involves PCR amplifications and gel
electrophoresis. This approach is cumbersome, and more importantly, fails to
detect very small internal tandem duplications as well as point mutations. Our
methodology, based on use of the WAVE System, has proven capable of detecting
all types of alterations in the FLT3 gene, including unanticipated mutations,
with sensitivity and specificity approaching 100%."
    Transgenomic scientists, led by Stan Lilleberg, Ph.D., director of
Discovery Services, recently presented results of WAVE-based FLT3 analyses at
the Association for Molecular Pathology's annual meeting held Nov. 20-23 in
Orlando, Fla. According to Dr. Lilleberg, "Our platforms, particularly the
WAVE HS System, offer the analytical sensitivity required to scan and/or score
for mutations that may only be present in a small percentage of leukemic
cells. Compared to other approaches, we have been able to demonstrate
increased analytical sensitivity for detection of both internal tandem
duplications and point mutations, by detecting variants present in less than
1% of the total FLT3 gene copies." He concluded, "We believe this has
important implications for the development of targeted therapeutics, selection
of appropriate therapeutic strategies for individual patients and post-
treatment monitoring."
    Other presentations by Transgenomic's customers at the ASH meeting will
cover various topics in a number of different scientific sessions that include
prognostic and diagnostic markers in leukemia, minimum residual disease and
diagnostic markers, pathogenesis/biology of myeloproliferative disorders and
von Willebrand Disease.

    About Transgenomic
    Transgenomic provides versatile and innovative research tools and related
consumable products to the life sciences industry for the synthesis,
separation, analysis and purification of nucleic acids and a wide variety of
nucleic acid-based specialty chemicals. Transgenomic's biosystems segment
offers its WAVE Systems and associated consumables. These systems are
specifically designed for use in genetic variation detection and single- and
double-strand DNA/RNA analysis and purification. These systems have broad
applicability to genetic research and molecular diagnostics. To date there
have been approximately one thousand systems installed in over 30 countries
around the world.
    Through its nucleic acids business segment, Transgenomic provides
specialty chemicals, including advanced nucleic acid building blocks and
associated reagents, used in applications such as genetic diagnostics and
therapeutics. Manufacturing operations include a cGMP facility for the
synthesis of oligonucleotides.
    For more information about the innovative genomics research tools
developed and marketed by Transgenomic, please visit the Company's Web site at
www.transgenomic.com .

    Forward-Looking Statement
    Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements include, but are not limited to, those
with respect to the importance that the detection sensitivity of the WAVE
System has to implications for the development of targeted therapeutics,
selection of appropriate therapeutic strategies for individual patients, and
post-treatment monitoring. The known risks, uncertainties and other factors
affecting these forward-looking statements are described from time to time in
Transgenomic's reports to the Securities and Exchange Commission. Any change
in such factors, risks and uncertainties may cause the actual results, events
and performance to differ materially from those referred to in such
statements. Accordingly, Transgenomic claims the protection of the safe harbor
for forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995 with respect to all statements contained in this press
release. All information in this press release is as of the date of the
release, and Transgenomic undertakes no duty to update this information,
including any forward-looking statement, unless required by law.

SOURCE Transgenomic, Inc.
    -0-                             12/04/2003
    /CONTACT:  Mitchell L. Murphy, +1-402-452-5437, mmurphy@transgenomic.com ,
or Robert J. Pogulis, Ph.D., +1-845-782-9617, rpogulis@transgenomic.com , both
of Transgenomic, Inc./
   /Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000314/CGTU026
           AP Archive: http://photoarchive.ap.org
           PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840/
    /Web site: http://www.transgenomic.com /
    (TBIO)
CO:  Transgenomic, Inc.; American Society of Hematology
ST:  Nebraska, California
IN:  MTC BIO
SU: